A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer
Clinical trial NCT07150767 · WITHDRAWN
Trial details
- NCT number
- NCT07150767
- Sponsor
- Beijing Bio-Targeting Therapeutics Technology Co., Ltd
- Status
- WITHDRAWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-26
- Primary completion
- 2027-03-26
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.